[Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
Multi-antibiotic resistant Gram-positive cocci represent emerging pathogens especially in the setting of the immunocompromised, hospitalized patients, in particular when surgery, invasive procedures, or prosthetic implants are of concern, patients are admitted in intensive care units, or underlying chronic disorders and immunodeficiency are of concern, and broad-spectrum antibiotics and/or immunosuppressive drugs are widely administered. The spectrum of available antimicrobial compounds for an effective management of these relevant infections is significantly impaired in selection and clinical efficacy by the emerging and spread of methicillin-resistant and more recently glycopeptide-resistant Gram-positive microbial strains linezolid, together with the recently licensed quinupristin-dalfopristin, daptomycin and tigecycline, followed by a number of glycopeptides, fluoroquinolones, and other experimental compounds represent an effective response to these concerns, due to their innovative mechanisms of action, their maintained or enhanced activity against multiresistant pathogens, their effective pharmacokinetic/pharmacodynamic properties, their frequent possibility of synergistic activity with other compounds effective against Gram-positive pathogens, and a diffuse potential for a safe and easy administration, also when compromised patients are of concern. The main problems related to the epidemiological and clinical features of multiresistant Gram-positive infection, the potential clinical indications of all recently available compounds compared with the standard of treatment of resistant Gram-positive infections, and updated data on efficacy and tolerability of linezolid have to be clarified.
Manfredi
Roberto
R
Sezione di Malattie Infettive, Dipartimento di Medicina Clinica Specialistica e Sperimentale, "Alma Mater Studiorum" Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna. roberto.manfredi@unibo.it
D000081:Acetamides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D017576:Daptomycin / Q000008:administration & dosage / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D016983:Enterococcus / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D023303:Oxazolidinones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D017334:Teicoplanin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000078304:Tigecycline; D013997:Time Factors; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use; D014769:Virginiamycin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D014769:Virginiamycin; C113825:quinupristin; D017334:Teicoplanin; D014640:Vancomycin; D000078304:Tigecycline; C469289:dalbavancin; D008911:Minocycline; D000069349:Linezolid; D017576:Daptomycin; C113826:dalfopristin